{ "run": { "id": "cmnr15eia06rbp658k9ftmb43", "region": "US", "assetId": "cmnr15egq06r3p658wftautm6", "ticker": "UNH", "snapshotId": "cmnr15ehw06r7p658896digkq", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:22:02.285Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr15ehw06r7p658896digkq", "assetId": "cmnr15egq06r3p658wftautm6", "asOf": "2026-04-08T20:00:00.000Z", "snapshot": { "asOf": "2026-04-08T20:00:00.000Z", "quote": { "asOf": "2026-04-08T20:00:00.000Z", "open": 312, "price": 305.98, "dayLow": 304.8317, "volume": 9645031, "dayHigh": 312.97, "currency": "USD", "prevClose": 307.73, "week52Low": 234.6, "week52High": 606.36 }, "fundamentals": { "pe": 24.8576807228916, "beta": 0.430572773350734, "epsTTM": 13.28, "fcfTTM": 15127000000, "growth": { "epsYoy": -0.1508951406649617, "revenueYoy": 0.1181403924272631 }, "sector": "Hospital & Medical Service Plans", "margins": { "net": 0.02693674913476642, "gross": null, "operating": 0.04237130977038075 }, "website": "https://unitedhealthgroup.com/", "industry": "Managed healthcare", "pegRatio": -1.64734799366959, "ebitdaTTM": 24133000000, "forwardPe": 18.6608253250424, "marketCap": 281907836350, "totalCash": 24365000000, "totalDebt": 78389000000, "debtEquity": 0.783185133379958, "quickRatio": 0.4147105668555315, "revenueTTM": 447567000000, "companyName": "UNITEDHEALTH GROUP INC", "priceToBook": 2.94735275029991, "currentRatio": 0.7883756756051071, "dividendYield": 0.0264095655206107, "returnOnAssets": 0.03894295838568904, "returnOnEquity": 0.120451593565791, "analystOpinions": null, "businessSummary": "UnitedHealth Group Incorporated is an American multinational for-profit company based in Eden Prairie, Minnesota specializing in health insurance and health care services. Selling insurance products under UnitedHealthcare, and health care services under the Optum brand, it is the world's seventh-largest company by revenue and the largest health care company by revenue. The company is ranked seventh on the 2025 Fortune Global 500.", "enterpriseValue": 353763880000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 390000, "sharesOutstanding": 907675839, "enterpriseToEbitda": 14.65892678075664, "analystTargetMedian": null, "enterpriseToRevenue": 0.7904154685220314, "operatingCashflowTTM": 19697000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:22:02.276Z" }, "results": [ { "id": "cmnr15eic06rip658mxdugy7w", "runId": "cmnr15eia06rbp658k9ftmb43", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"claude-sonnet-4-20250514\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"UNH\",\"currency\":\"USD\",\"current_price\":305.98,\"target_price_6m\":335,\"target_price_12m\":355,\"recommendation\":\"BUY\",\"confidence\":0.55,\"thesis_bullets\":[\"Stock ~50% off 52-week high creates potential value entry point\",\"Forward PE 18.7x is historically cheap for UNH quality franchise\",\"Revenue still growing 11.8% YoY despite margin headwinds\",\"FCF of $15.1B supports dividend and potential buyback acceleration\",\"Regulatory and legal overhang creates uncertainty but may be priced in\"],\"key_drivers\":[{\"driver\":\"Medical loss ratio trajectory and cost containment\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"DOJ/regulatory investigations resolution timeline\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Optum Health and Optum Rx revenue diversification\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Medicare Advantage enrollment and reimbursement rates\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"PBM reform legislative risk\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Commercial enrollment growth in employer segment\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Debt load at 0.78x D/E limiting financial flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Dividend yield at 2.6% providing downside support\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"DOJ Medicare billing investigation could result in material fines or structural remedies\",\"Continued medical cost inflation compressing already thin operating margins\",\"Legislative PBM reform could structurally impair Optum Rx profitability\",\"Management credibility concerns following leadership disruptions\",\"Liquidity risk with current ratio below 1.0 and quick ratio at 0.41\"],\"assumptions\":{\"revenue_cagr_3y\":0.09,\"ebit_margin_target\":0.055,\"wacc\":0.09,\"terminal_multiple\":16},\"scenarios\":{\"bear\":{\"target_price\":240,\"prob\":0.25,\"notes\":\"Regulatory penalties materialize, MLR stays elevated, earnings decline further.\"},\"base\":{\"target_price\":355,\"prob\":0.50,\"notes\":\"Margins stabilize, Optum drives gradual EPS recovery toward $19-20.\"},\"bull\":{\"target_price\":450,\"prob\":0.25,\"notes\":\"Legal overhang clears, margin recovery accelerates, multiple re-rates upward.\"}},\"method_notes\":\"Earnings-power valuation: forward EPS ~$16.4 (snapshot forward PE) growing to ~$19-20 on margin recovery, applied 17-18x normalized PE. Stock at ~50% of 52-week high reflects severe overhang; valuation appears cheap historically but justified by real fundamental risks (MLR, legal). Weighted scenario EV ~$350 supports base target. Confidence moderate (0.55) due to binary regulatory outcomes and margin uncertainty. Sell-side targets noted but not used as inputs. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "claude-sonnet-4-20250514", "risks": [ "DOJ Medicare billing investigation could result in material fines or structural remedies", "Continued medical cost inflation compressing already thin operating margins", "Legislative PBM reform could structurally impair Optum Rx profitability", "Management credibility concerns following leadership disruptions", "Liquidity risk with current ratio below 1.0 and quick ratio at 0.41" ], "ticker": "UNH", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Margins stabilize, Optum drives gradual EPS recovery toward $19-20.", "target_price": 355 }, "bear": { "prob": 0.25, "notes": "Regulatory penalties materialize, MLR stays elevated, earnings decline further.", "target_price": 240 }, "bull": { "prob": 0.25, "notes": "Legal overhang clears, margin recovery accelerates, multiple re-rates upward.", "target_price": 450 } }, "confidence": 0.55, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.09, "terminal_multiple": 16, "ebit_margin_target": 0.055 }, "key_drivers": [ { "driver": "Medical loss ratio trajectory and cost containment", "impact": "HIGH", "direction": "NEG" }, { "driver": "DOJ/regulatory investigations resolution timeline", "impact": "HIGH", "direction": "NEG" }, { "driver": "Optum Health and Optum Rx revenue diversification", "impact": "HIGH", "direction": "POS" }, { "driver": "Medicare Advantage enrollment and reimbursement rates", "impact": "HIGH", "direction": "POS" }, { "driver": "PBM reform legislative risk", "impact": "MED", "direction": "NEG" }, { "driver": "Commercial enrollment growth in employer segment", "impact": "MED", "direction": "POS" }, { "driver": "Debt load at 0.78x D/E limiting financial flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend yield at 2.6% providing downside support", "impact": "LOW", "direction": "POS" } ], "method_notes": "Earnings-power valuation: forward EPS ~$16.4 (snapshot forward PE) growing to ~$19-20 on margin recovery, applied 17-18x normalized PE. Stock at ~50% of 52-week high reflects severe overhang; valuation appears cheap historically but justified by real fundamental risks (MLR, legal). Weighted scenario EV ~$350 supports base target. Confidence moderate (0.55) due to binary regulatory outcomes and margin uncertainty. Sell-side targets noted but not used as inputs. Not investment advice.", "current_price": 305.98, "recommendation": "BUY", "thesis_bullets": [ "Stock ~50% off 52-week high creates potential value entry point", "Forward PE 18.7x is historically cheap for UNH quality franchise", "Revenue still growing 11.8% YoY despite margin headwinds", "FCF of $15.1B supports dividend and potential buyback acceleration", "Regulatory and legal overhang creates uncertainty but may be priced in" ], "target_price_6m": 335, "target_price_12m": 355 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 37945, "createdAt": "2026-04-09T05:22:02.285Z", "usage": { "inputTokens": 3611, "outputTokens": 1673, "costUsd": 0.05988 } }, { "id": "cmnr15eic06rlp6589ctzpq3n", "runId": "cmnr15eia06rbp658k9ftmb43", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Model Recommendation\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"UNH\",\n \"currency\": \"USD\",\n \"current_price\": 305.98,\n \"target_price_6m\": 308.0,\n \"target_price_12m\": 310.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Revenue growth robust at 11.8% YoY.\",\n \"EPS decline of 15.1% YoY raises concerns.\",\n \"Optum services driving long-term value.\",\n \"Regulatory uncertainty poses significant risks.\",\n \"Valuation implies limited near-term upside.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Revenue growth from health services\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"EPS pressure from medical costs\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Regulatory changes in healthcare\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Market position and brand strength\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt and leverage levels\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Innovation in digital health\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Economic sensitivity\", \"impact\": \"LOW\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\n \"Healthcare policy reforms\",\n \"Competitive intensity increasing\",\n \"Cybersecurity incidents\",\n \"Economic recession impacting enrollment\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.07,\n \"ebit_margin_target\": 0.045,\n \"wacc\": 0.07,\n \"terminal_multiple\": 18\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 290.0, \"prob\": 0.2, \"notes\": \"Adverse regulatory changes and high costs.\" },\n \"base\": { \"target_price\": 310.0, \"prob\": 0.6, \"notes\": \"Moderate growth and stable margins.\" },\n \"bull\": { \"target_price\": 330.0, \"prob\": 0.2, \"notes\": \"Strong execution and favorable market conditions.\" }\n },\n \"method_notes\": \"Valuation based on forward P/E and growth assumptions. HOLD due to balanced risk-reward and mixed fundamentals. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Model Recommendation", "risks": [ "Healthcare policy reforms", "Competitive intensity increasing", "Cybersecurity incidents", "Economic recession impacting enrollment" ], "ticker": "UNH", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Moderate growth and stable margins.", "target_price": 310 }, "bear": { "prob": 0.2, "notes": "Adverse regulatory changes and high costs.", "target_price": 290 }, "bull": { "prob": 0.2, "notes": "Strong execution and favorable market conditions.", "target_price": 330 } }, "confidence": 0.6, "assumptions": { "wacc": 0.07, "revenue_cagr_3y": 0.07, "terminal_multiple": 18, "ebit_margin_target": 0.045 }, "key_drivers": [ { "driver": "Revenue growth from health services", "impact": "HIGH", "direction": "POS" }, { "driver": "EPS pressure from medical costs", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory changes in healthcare", "impact": "HIGH", "direction": "NEG" }, { "driver": "Market position and brand strength", "impact": "MED", "direction": "POS" }, { "driver": "Debt and leverage levels", "impact": "LOW", "direction": "NEG" }, { "driver": "Innovation in digital health", "impact": "MED", "direction": "POS" }, { "driver": "Economic sensitivity", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on forward P/E and growth assumptions. HOLD due to balanced risk-reward and mixed fundamentals. Not investment advice.", "current_price": 305.98, "recommendation": "HOLD", "thesis_bullets": [ "Revenue growth robust at 11.8% YoY.", "EPS decline of 15.1% YoY raises concerns.", "Optum services driving long-term value.", "Regulatory uncertainty poses significant risks.", "Valuation implies limited near-term upside." ], "target_price_6m": 308, "target_price_12m": 310 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 357, "createdAt": "2026-04-09T05:22:02.285Z", "usage": { "inputTokens": 2115, "outputTokens": 3242, "costUsd": 0.001954 } }, { "id": "cmnr15eic06rjp6584eqrdm17", "runId": "cmnr15eia06rbp658k9ftmb43", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_v1\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"UNH\",\n \"currency\": \"USD\",\n \"current_price\": 305.98,\n \"target_price_6m\": 335.00,\n \"target_price_12m\": 365.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.70,\n \"thesis_bullets\": [\n \"Massive 50% pullback from 52-week highs prices in overly pessimistic Medicare Advantage scenarios.\",\n \"Optum's double-digit revenue growth provides a strong buffer against insurance margin compression.\",\n \"Elevated Medical Loss Ratios (MLR) are likely to normalize over the next 12-18 months.\",\n \"Forward P/E of 18.6x is highly attractive for a historically premium-valued market leader.\",\n \"Regulatory scrutiny and antitrust probes remain significant near-term overhangs limiting multiple expansion.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Medicare Advantage Rates\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Optum Health Revenue Growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medical Loss Ratio (MLR) Trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"DOJ Antitrust Probe\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Value-Based Care Penetration\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Share Repurchase Program\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Change Healthcare Recovery\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Sustained increases in senior outpatient utilization driving up MLR.\",\n \"Stricter CMS rate notices for Medicare Advantage compressing margins.\",\n \"DOJ antitrust actions forcing structural changes between UnitedHealthcare and Optum.\",\n \"Lingering reputational and financial costs from cyberattacks.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.065,\n \"wacc\": 0.075,\n \"terminal_multiple\": 16.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 250.00,\n \"prob\": 0.25,\n \"notes\": \"MLR remains elevated and CMS cuts MA rates further, compressing EPS.\"\n },\n \"base\": {\n \"target_price\": 365.00,\n \"prob\": 0.60,\n \"notes\": \"MLR normalizes and Optum drives steady growth, leading to multiple mean reversion.\"\n },\n \"bull\": {\n \"target_price\": 450.00,\n \"prob\": 0.15,\n \"notes\": \"Utilization drops sharply and regulatory overhang clears, restoring historical premium valuation.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF and historical P/E mean reversion. Target implies ~19% upside, supporting a BUY rating. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "EquityResearch_v1", "risks": [ "Sustained increases in senior outpatient utilization driving up MLR.", "Stricter CMS rate notices for Medicare Advantage compressing margins.", "DOJ antitrust actions forcing structural changes between UnitedHealthcare and Optum.", "Lingering reputational and financial costs from cyberattacks." ], "ticker": "UNH", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "MLR normalizes and Optum drives steady growth, leading to multiple mean reversion.", "target_price": 365 }, "bear": { "prob": 0.25, "notes": "MLR remains elevated and CMS cuts MA rates further, compressing EPS.", "target_price": 250 }, "bull": { "prob": 0.15, "notes": "Utilization drops sharply and regulatory overhang clears, restoring historical premium valuation.", "target_price": 450 } }, "confidence": 0.7, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.08, "terminal_multiple": 16, "ebit_margin_target": 0.065 }, "key_drivers": [ { "driver": "Medicare Advantage Rates", "impact": "HIGH", "direction": "NEG" }, { "driver": "Optum Health Revenue Growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Medical Loss Ratio (MLR) Trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "DOJ Antitrust Probe", "impact": "MED", "direction": "NEG" }, { "driver": "Value-Based Care Penetration", "impact": "MED", "direction": "POS" }, { "driver": "Share Repurchase Program", "impact": "LOW", "direction": "POS" }, { "driver": "Change Healthcare Recovery", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on a 10-year DCF and historical P/E mean reversion. Target implies ~19% upside, supporting a BUY rating. Not investment advice.", "current_price": 305.98, "recommendation": "BUY", "thesis_bullets": [ "Massive 50% pullback from 52-week highs prices in overly pessimistic Medicare Advantage scenarios.", "Optum's double-digit revenue growth provides a strong buffer against insurance margin compression.", "Elevated Medical Loss Ratios (MLR) are likely to normalize over the next 12-18 months.", "Forward P/E of 18.6x is highly attractive for a historically premium-valued market leader.", "Regulatory scrutiny and antitrust probes remain significant near-term overhangs limiting multiple expansion." ], "target_price_6m": 335, "target_price_12m": 365 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 25304, "createdAt": "2026-04-09T05:22:02.285Z", "usage": { "inputTokens": 2484, "outputTokens": 878, "costUsd": 0.015504 } }, { "id": "cmnr15eic06rhp658f32i6zpm", "runId": "cmnr15eia06rbp658k9ftmb43", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"UNH\",\"currency\":\"USD\",\"current_price\":305.98,\"target_price_6m\":322,\"target_price_12m\":336,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Revenue growth remains solid despite temporary earnings pressure.\",\"Forward P/E implies muted recovery versus historical quality.\",\"Optum diversification supports cash flow and resilience.\",\"Low beta and dividend improve total-return profile.\",\"Margins, utilization, and regulation keep upside capped.\"],\"key_drivers\":[{\"driver\":\"Medicare Advantage utilization normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Optum Health and Rx scale\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Forward earnings recovery\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Medical cost trend pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Rate and reimbursement changes\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory and antitrust scrutiny\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Strong free cash flow\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Balance sheet leverage manageable\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Persistently elevated care utilization\",\"Medicare Advantage funding cuts\",\"Regulatory or litigation setbacks\",\"Optum execution disappoints\",\"Margin recovery takes longer\"],\"assumptions\":{\"revenue_cagr_3y\":0.08,\"ebit_margin_target\":0.05,\"wacc\":0.09,\"terminal_multiple\":16},\"scenarios\":{\"bear\":{\"target_price\":260,\"prob\":0.3,\"notes\":\"Costs stay elevated and policy pressure compresses multiples.\"},\"base\":{\"target_price\":336,\"prob\":0.45,\"notes\":\"Earnings recover gradually as utilization normalizes and Optum grows.\"},\"bull\":{\"target_price\":395,\"prob\":0.25,\"notes\":\"Faster margin rebound and stronger Optum mix drive rerating.\"}},\"method_notes\":\"Targets use a blended forward earnings and EV/EBITDA view anchored to snapshot fundamentals; quote fields kept exactly from snapshot. BUY fits ~9.8% 12M upside with moderate uncertainty. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Model Recommendation", "risks": [ "Persistently elevated care utilization", "Medicare Advantage funding cuts", "Regulatory or litigation setbacks", "Optum execution disappoints", "Margin recovery takes longer" ], "ticker": "UNH", "currency": "USD", "scenarios": { "base": { "prob": 0.45, "notes": "Earnings recover gradually as utilization normalizes and Optum grows.", "target_price": 336 }, "bear": { "prob": 0.3, "notes": "Costs stay elevated and policy pressure compresses multiples.", "target_price": 260 }, "bull": { "prob": 0.25, "notes": "Faster margin rebound and stronger Optum mix drive rerating.", "target_price": 395 } }, "confidence": 0.62, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.08, "terminal_multiple": 16, "ebit_margin_target": 0.05 }, "key_drivers": [ { "driver": "Medicare Advantage utilization normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Optum Health and Rx scale", "impact": "HIGH", "direction": "POS" }, { "driver": "Forward earnings recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Medical cost trend pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Rate and reimbursement changes", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory and antitrust scrutiny", "impact": "MED", "direction": "NEG" }, { "driver": "Strong free cash flow", "impact": "MED", "direction": "POS" }, { "driver": "Balance sheet leverage manageable", "impact": "LOW", "direction": "POS" } ], "method_notes": "Targets use a blended forward earnings and EV/EBITDA view anchored to snapshot fundamentals; quote fields kept exactly from snapshot. BUY fits ~9.8% 12M upside with moderate uncertainty. not investment advice", "current_price": 305.98, "recommendation": "BUY", "thesis_bullets": [ "Revenue growth remains solid despite temporary earnings pressure.", "Forward P/E implies muted recovery versus historical quality.", "Optum diversification supports cash flow and resilience.", "Low beta and dividend improve total-return profile.", "Margins, utilization, and regulation keep upside capped." ], "target_price_6m": 322, "target_price_12m": 336 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_008b45ce8670e65a0069d75e520f2081979a1ee2e210a5d923", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 19751, "createdAt": "2026-04-09T05:22:02.285Z", "usage": { "inputTokens": 2385, "outputTokens": 989, "costUsd": 0.01802 } }, { "id": "cmnr15eic06rkp658omqdp4g7", "runId": "cmnr15eia06rbp658k9ftmb43", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"UNH\",\n \"currency\": \"USD\",\n \"current_price\": 305.98,\n \"target_price_6m\": 325,\n \"target_price_12m\": 350,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Diversified model via UnitedHealthcare and Optum drives stability\",\n \"Strong cash flow funds dividends and ongoing share repurchases\",\n \"Pullback from 52w highs offers attractive valuation entry\",\n \"Regulatory risks in Medicare Advantage may constrain growth\",\n \"Recent EPS decline signals near-term margin and cost pressures\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Optum services growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Aging population demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medicare policy changes\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Medical loss ratio control\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Industry competition intensity\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Revenue diversification\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt burden and rates\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Tech-enabled efficiencies\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Regulatory changes to Medicare Advantage\",\n \"Rising medical loss ratios\",\n \"Healthcare reform legislation\",\n \"Cybersecurity and data breaches\",\n \"Acquisition integration failures\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.1,\n \"ebit_margin_target\": 0.05,\n \"wacc\": 0.085,\n \"terminal_multiple\": 16\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 250,\n \"prob\": 0.3,\n \"notes\": \"Severe regulatory crackdown hurts margins.\"\n },\n \"base\": {\n \"target_price\": 350,\n \"prob\": 0.5,\n \"notes\": \"Moderate growth and stable operations continue.\"\n },\n \"bull\": {\n \"target_price\": 420,\n \"prob\": 0.2,\n \"notes\": \"Strong Optum performance drives market share gains.\"\n }\n },\n \"method_notes\": \"DCF using 10% revenue CAGR, 5% EBIT margin target, 8.5% WACC and 16x terminal multiple; 14% 12M upside supports BUY. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Equity Research Model", "risks": [ "Regulatory changes to Medicare Advantage", "Rising medical loss ratios", "Healthcare reform legislation", "Cybersecurity and data breaches", "Acquisition integration failures" ], "ticker": "UNH", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate growth and stable operations continue.", "target_price": 350 }, "bear": { "prob": 0.3, "notes": "Severe regulatory crackdown hurts margins.", "target_price": 250 }, "bull": { "prob": 0.2, "notes": "Strong Optum performance drives market share gains.", "target_price": 420 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.1, "terminal_multiple": 16, "ebit_margin_target": 0.05 }, "key_drivers": [ { "driver": "Optum services growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Aging population demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Medicare policy changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Medical loss ratio control", "impact": "MED", "direction": "POS" }, { "driver": "Industry competition intensity", "impact": "MED", "direction": "NEG" }, { "driver": "Revenue diversification", "impact": "MED", "direction": "POS" }, { "driver": "Debt burden and rates", "impact": "LOW", "direction": "NEG" }, { "driver": "Tech-enabled efficiencies", "impact": "MED", "direction": "POS" } ], "method_notes": "DCF using 10% revenue CAGR, 5% EBIT margin target, 8.5% WACC and 16x terminal multiple; 14% 12M upside supports BUY. Not investment advice.", "current_price": 305.98, "recommendation": "BUY", "thesis_bullets": [ "Diversified model via UnitedHealthcare and Optum drives stability", "Strong cash flow funds dividends and ongoing share repurchases", "Pullback from 52w highs offers attractive valuation entry", "Regulatory risks in Medicare Advantage may constrain growth", "Recent EPS decline signals near-term margin and cost pressures" ], "target_price_6m": 325, "target_price_12m": 350 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "aa2df3ef-254b-9182-a765-c653f22b825b", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 14170, "createdAt": "2026-04-09T05:22:02.285Z", "usage": { "inputTokens": 2725, "outputTokens": 2801, "costUsd": 0.05019 } } ] } }